Published in Medical Letter on the CDC and FDA, May 3rd, 2009
"Dr. Les Nagata and his research team at DRDC are leaders in developing vaccines to fight deadly microbial pathogens and we look forward to this collaboration," remarked Dr. Marc Mansour, vice president of R&D at IVT. "Because our DepoVax(TM) formulation creates a long-lasting immune...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA